

Sectoral Asset Management launches new biotech fund

Montreal/Geneva, 06 June 2016. Sectoral Asset Management launches its new biotech vehicle, the Variopartner SICAV - Sectoral Biotech Opportunities Fund with starting assets of over USD50 million. This fund invests in innovative biotech companies with an emphasis on small and mid caps and has therefore a unique positioning in the market. It will be an interesting possibility for private and institutional investors as valuations of biotech companies are currently attractive.

Sectoral Asset Management has been successfully managing Biotech strategies since 1994, with a 15.3% gross annualized return (15.0% net) of its Biotech composite and a 24.7% gross annualized return¹ (22.1% net) of its Small and Mid Cap Biotech composite. Sectoral's specialized knowledge and extensive research capabilities allow the new fund to proactively seek out and evaluate cutting-edge technologies and companies in the global biotech industry. Michael Sjöström, CFA, CIO and co-founder of Sectoral, commented: "This new fund is clearly differentiated from large traditional biotech funds and ETFs".

Mina Marmor, Ph.D., CFA and portfolio manager of the Sectoral Biotech Opportunities Fund, added: "After the recent correction, biotech valuations have retreated to levels not seen in five years. Given the strong pipeline of the industry, a favourable regulatory framework for drugs targeting rare or severe diseases and the growing demand for innovative drugs, the industry is poised to deliver attractive returns to investors." Medical innovation is accelerating the pace of new product development, as measured by new drug approvals. Innovation is particularly strong in the areas of cancer and gene therapy. Last year was a record year in terms of new product launches. 45 new drugs, most of them coming from the biotech industry, have been approved by the FDA.

The Sectoral Biotech Opportunities Fund invests in innovative biotech companies, with an emphasis on small and mid caps. It targets around 30 high conviction positions and is built from bottom up. The fund size target is USD300-USD500 million. The fund assets at commercial launch are over USD50 million. Part of the starting fund assets were raised by Bonhôte Fund Solutions, an investment platform that comprises the eponymous bank, Bordier & Cie as well as other institutional partners.

Share classes

	P-EUR	I-EUR	P-USD	I-USD
Bloomberg ticker	VSGPEUR LX	VSGIEUR LX	VSGPUSD LX	VSGIUSD LX
ISIN	LU1176838347	LU1176837026	LU1176840327	LU1176839154
Management Fee (p.a.) in %	1.80	0.90	1.80	0.90
Available to	Retail & Institutional investors	Institutional investors	Retail & Institutional investors	Institutional investors
Minimum Initial Subscription	1 Share	EUR50,000	1 Share	USD50,000

About Sectoral

Founded in 2000, Sectoral Asset Management is an industry-leading specialist in managing global investment portfolios in the healthcare sector. Sectoral maintains offices in Montreal, Geneva, and Hong Kong. Sectoral's investment philosophy is based on fundamental research in the healthcare sector.

1. Gross performance as of December 31, 2015 which does not include management fees and other administrative expenses.

Important legal disclaimer

Variopartner SICAV - Sectoral Biotech Opportunities Fund is a compartment of Variopartner SICAV, an investment fund under Luxembourg law. This document is not an offer to purchase or subscribe shares of the SICAV. Before any investment, we suggest you contact your personal advisor or other advisors. Past performance is not indicative of future results. Please carefully read the prospectus published and available free of charge from the distribution agents or at the correspondent banks or at the SICAV headquarters or on www.sectoral.com, together with the document containing key information for investors (KIID), the Articles of Association, the annual and half-yearly report and the subscription form. The performance of the Fund may increase or decrease due to fluctuations in exchange rates between currencies. An investment in the compartment of Variopartner SICAV entails risks which are described in the Prospectus. SECTORAL357